Skip to main content
Top
Published in: Annals of Surgical Oncology 2/2017

Open Access 01-02-2017 | Hepatobiliary Tumors

The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer

Authors: Michał Grąt, MD, PhD, Karolina M. Wronka, MD, Jan Stypułkowski, Emil Bik, Maciej Krasnodębski, MD, Łukasz Masior, MD, Zbigniew Lewandowski, PhD, Karolina Grąt, MD, Waldemar Patkowski, MD, PhD, Marek Krawczyk, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2017

Login to get access

Abstract

Background

Combination of the University of California, San Francisco (UCSF) and the up-to-7 criteria with alpha-fetoprotein (AFP) cutoff of 100 ng/ml was proposed as the Warsaw expansion of the Milan criteria in selection of hepatocellular cancer (HCC) patients for liver transplantation. The purpose of this retrospective study was to validate this proposal.

Methods

A total of 240 HCC patients after liver transplantation were included. Recurrence-free survival and overall survival at 5 years were set as the primary and secondary outcome measures, respectively.

Results

The Warsaw expansion increased transplant eligibility rate by 20.3 %. AFP >100 ng/ml significantly increased the recurrence risk in patients within the Milan criteria (p = 0.025) and in those beyond, yet within either the UCSF or the up-to-7 criteria (p < 0.001). Recurrence-free survival at 5 years was 90.8 % for patients within the Milan criteria, 100.0 % in patients within the Warsaw expansion, 54.9 % in patients beyond the Warsaw expansion but within either the UCSF or the up-to-7 criteria, and 45.1 % in patients beyond both the UCSF and the up-to-7 criteria (p < 0.001). The corresponding overall survival rates were 71.6, 82.4, 64.3, and 55.3 %, respectively (p = 0.027).

Conclusions

The Warsaw expansion of the Milan criteria substantially increases the recipient pool without compromising outcomes.
Literature
2.
go back to reference Kumar A, Acharya SK, Singh SP, et al. The Indian National Association for Study of the Liver (INASL) consensus on prevention, diagnosis and management of hepatocellular carcinoma in India: the Puri recommendations. J Clin Exp Hepatol. 2014;4(Suppl 3):S3–26.CrossRefPubMedPubMedCentral Kumar A, Acharya SK, Singh SP, et al. The Indian National Association for Study of the Liver (INASL) consensus on prevention, diagnosis and management of hepatocellular carcinoma in India: the Puri recommendations. J Clin Exp Hepatol. 2014;4(Suppl 3):S3–26.CrossRefPubMedPubMedCentral
3.
go back to reference Chapman WC, Klintmalm G, Hemming A, et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg. 2015;220:628–37.CrossRefPubMed Chapman WC, Klintmalm G, Hemming A, et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg. 2015;220:628–37.CrossRefPubMed
4.
go back to reference Seshadri RM, Besur S, Niemeyer DJ, et al. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford). 2014;16:1102–9.CrossRefPubMedPubMedCentral Seshadri RM, Besur S, Niemeyer DJ, et al. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford). 2014;16:1102–9.CrossRefPubMedPubMedCentral
5.
go back to reference Squires MH 3rd, Hanish SI, Fisher SB, et al. Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. J Surg Oncol. 2014;109:533–41.CrossRefPubMed Squires MH 3rd, Hanish SI, Fisher SB, et al. Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. J Surg Oncol. 2014;109:533–41.CrossRefPubMed
6.
go back to reference Zheng Z, Liang W, Milgrom DP, et al. Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies. Transplantation. 2014;97:227–34.CrossRefPubMed Zheng Z, Liang W, Milgrom DP, et al. Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies. Transplantation. 2014;97:227–34.CrossRefPubMed
7.
go back to reference Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? HPB (Oxford). 2011;13:783–91.CrossRefPubMedPubMedCentral Landman MP, Feurer ID, Pinson CW, Moore DE. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? HPB (Oxford). 2011;13:783–91.CrossRefPubMedPubMedCentral
8.
go back to reference Lai Q, Avolio AW, Lerut J, et al. Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in east and west. J Hepatol. 2012;57:974–9.CrossRefPubMed Lai Q, Avolio AW, Lerut J, et al. Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in east and west. J Hepatol. 2012;57:974–9.CrossRefPubMed
9.
go back to reference Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.CrossRefPubMed Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.CrossRefPubMed
10.
go back to reference Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11–22.CrossRefPubMed Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11–22.CrossRefPubMed
11.
go back to reference Bonadio I, Colle I, Geerts A, et al. Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asian criteria: long-term follow-up of a Western single institutional experience. Clin Transplant. 2015;29:425–33.CrossRefPubMed Bonadio I, Colle I, Geerts A, et al. Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asian criteria: long-term follow-up of a Western single institutional experience. Clin Transplant. 2015;29:425–33.CrossRefPubMed
12.
go back to reference Fan J, Yang GS, Fu ZR, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol. 2009;135:1403–12.CrossRefPubMed Fan J, Yang GS, Fu ZR, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol. 2009;135:1403–12.CrossRefPubMed
13.
go back to reference Shirabe K, Taketomi A, Morita K, et al. Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation. Clin Transplant. 2011;25:E491–8.CrossRefPubMed Shirabe K, Taketomi A, Morita K, et al. Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation. Clin Transplant. 2011;25:E491–8.CrossRefPubMed
14.
go back to reference Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.CrossRefPubMed Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.CrossRefPubMed
15.
go back to reference Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.CrossRefPubMed Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.CrossRefPubMed
16.
go back to reference Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95:755–60.CrossRefPubMed Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013;95:755–60.CrossRefPubMed
17.
go back to reference Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME, Florman SS. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology. 2015;61:895–904.CrossRefPubMed Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME, Florman SS. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology. 2015;61:895–904.CrossRefPubMed
18.
go back to reference Piardi T, Gheza F, Ellero B, et al. Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2012;19:2020–6.CrossRefPubMed Piardi T, Gheza F, Ellero B, et al. Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2012;19:2020–6.CrossRefPubMed
19.
go back to reference Cheah YL, Chow PKH. Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies. Liver Cancer. 2012;1:183–9.CrossRef Cheah YL, Chow PKH. Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies. Liver Cancer. 2012;1:183–9.CrossRef
20.
go back to reference Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, Freeman RB. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl. 2011;17(Suppl 2):S81–9.CrossRefPubMed Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, Freeman RB. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl. 2011;17(Suppl 2):S81–9.CrossRefPubMed
21.
go back to reference Durand F, Belghiti J. Liver transplantation for hepatocellular carcinoma: should we push the limits? Liver Transplant. 2003;9:697–9.CrossRefPubMed Durand F, Belghiti J. Liver transplantation for hepatocellular carcinoma: should we push the limits? Liver Transplant. 2003;9:697–9.CrossRefPubMed
22.
go back to reference Tanaka T, Kurosaki M, Lilly LB, Izumi N, Sherman M. Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: data mining analysis. J Surg Oncol. 2015;112:72–9.CrossRefPubMed Tanaka T, Kurosaki M, Lilly LB, Izumi N, Sherman M. Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: data mining analysis. J Surg Oncol. 2015;112:72–9.CrossRefPubMed
23.
go back to reference Chaiteerakij R, Zhang X, Addissie BD, et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transplant. 2015;21:599–606.CrossRefPubMedPubMedCentral Chaiteerakij R, Zhang X, Addissie BD, et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transplant. 2015;21:599–606.CrossRefPubMedPubMedCentral
24.
go back to reference Lai Q, Avolio AW, Graziadei I, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transplant. 2013;19:1108–18.CrossRefPubMed Lai Q, Avolio AW, Graziadei I, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transplant. 2013;19:1108–18.CrossRefPubMed
25.
go back to reference Hu Z, Zhou J, Wang H, et al. Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010. PLoS One. 2013;8:e61620.CrossRefPubMedPubMedCentral Hu Z, Zhou J, Wang H, et al. Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010. PLoS One. 2013;8:e61620.CrossRefPubMedPubMedCentral
26.
go back to reference Yang SH, Suh KS, Lee HW, et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery. 2007;141:598–609.CrossRefPubMed Yang SH, Suh KS, Lee HW, et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery. 2007;141:598–609.CrossRefPubMed
27.
go back to reference Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85:1726–32.CrossRefPubMed Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85:1726–32.CrossRefPubMed
28.
go back to reference Taketomi A, Sanefuji K, Soejima Y, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531–7.CrossRefPubMed Taketomi A, Sanefuji K, Soejima Y, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531–7.CrossRefPubMed
29.
go back to reference Takada Y, Ito T, Ueda M, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis. 2007;25:299–302.CrossRefPubMed Takada Y, Ito T, Ueda M, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis. 2007;25:299–302.CrossRefPubMed
30.
go back to reference Shindoh J, Sugawara Y, Nagata R, et al. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2014;27:391-8.CrossRefPubMed Shindoh J, Sugawara Y, Nagata R, et al. Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2014;27:391-8.CrossRefPubMed
31.
go back to reference Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–94.CrossRefPubMed Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–94.CrossRefPubMed
32.
go back to reference Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009;49:832–8.CrossRefPubMed Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009;49:832–8.CrossRefPubMed
33.
go back to reference Grąt M, Kornasiewicz O, Lewandowski Z, et al. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg. 2014;38:2698–707.CrossRefPubMedPubMedCentral Grąt M, Kornasiewicz O, Lewandowski Z, et al. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg. 2014;38:2698–707.CrossRefPubMedPubMedCentral
34.
go back to reference Krawczyk M, Grąt M, Barski K, et al. 1000 liver transplantations at the Department of General, Transplant and Liver Surgery, Medical University of Warsaw: analysis of indications and results. Pol Przegl Chir. 2012;84:304–12.PubMed Krawczyk M, Grąt M, Barski K, et al. 1000 liver transplantations at the Department of General, Transplant and Liver Surgery, Medical University of Warsaw: analysis of indications and results. Pol Przegl Chir. 2012;84:304–12.PubMed
35.
go back to reference Krawczyk M, Grąt M, Grąt K, et al. Evolution of the results Of 1500 liver transplantations performed In The Department Of General, Transplant And Liver Surgery Medical University Of Warsaw. Pol Przegl Chir. 2015;87:221–30.PubMed Krawczyk M, Grąt M, Grąt K, et al. Evolution of the results Of 1500 liver transplantations performed In The Department Of General, Transplant And Liver Surgery Medical University Of Warsaw. Pol Przegl Chir. 2015;87:221–30.PubMed
36.
go back to reference Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7:2587–96.CrossRefPubMed Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7:2587–96.CrossRefPubMed
37.
go back to reference Fernández JA, Robles R, Marin C, et al. Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc. 2003;35:1818–20.CrossRefPubMed Fernández JA, Robles R, Marin C, et al. Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc. 2003;35:1818–20.CrossRefPubMed
38.
go back to reference Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transplant. 2006;12:1761–9.CrossRefPubMed Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transplant. 2006;12:1761–9.CrossRefPubMed
39.
go back to reference de Ataide EC, Garcia M, Mattosinho TJ, Almeida JR, Escanhoela CA, Boin IF. Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma. Transplant Proc. 2012;44:2438–40.CrossRefPubMed de Ataide EC, Garcia M, Mattosinho TJ, Almeida JR, Escanhoela CA, Boin IF. Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma. Transplant Proc. 2012;44:2438–40.CrossRefPubMed
40.
go back to reference Harimoto N, Shirabe K, Nakagawara H, et al. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio. Transplantation. 2013;96:1008–12.CrossRefPubMed Harimoto N, Shirabe K, Nakagawara H, et al. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio. Transplantation. 2013;96:1008–12.CrossRefPubMed
42.
go back to reference Unek T, Karademir S, Arslan NC, et al. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World J Gastroenterol. 2011;17:4206–12.CrossRefPubMedPubMedCentral Unek T, Karademir S, Arslan NC, et al. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World J Gastroenterol. 2011;17:4206–12.CrossRefPubMedPubMedCentral
43.
go back to reference Vitale A, Farinati F, Burra P, et al. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: a multicenter cohort study using the alpha-fetoprotein model as a survival predictor. Liver Transplant 2015;21:1250–8.CrossRefPubMed Vitale A, Farinati F, Burra P, et al. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: a multicenter cohort study using the alpha-fetoprotein model as a survival predictor. Liver Transplant 2015;21:1250–8.CrossRefPubMed
44.
go back to reference Varona MA, Soriano A, Aguirre-Jaime A, et al. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. Transplant Proc. 2015;47:84–9.CrossRefPubMed Varona MA, Soriano A, Aguirre-Jaime A, et al. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. Transplant Proc. 2015;47:84–9.CrossRefPubMed
45.
go back to reference Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology. 2015;62:158–65.CrossRefPubMed Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology. 2015;62:158–65.CrossRefPubMed
46.
go back to reference Grat M, Kornasiewicz O, Hołówko W, Lewandowski Z, Zieniewicz K, Paczek L, Krawczyk M. Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer. Transplant Proc 2013;45:1899–903.CrossRefPubMed Grat M, Kornasiewicz O, Hołówko W, Lewandowski Z, Zieniewicz K, Paczek L, Krawczyk M. Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer. Transplant Proc 2013;45:1899–903.CrossRefPubMed
47.
go back to reference Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int. 2009;22:869–75.CrossRefPubMed Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int. 2009;22:869–75.CrossRefPubMed
48.
go back to reference Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10:129–37.CrossRefPubMed Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10:129–37.CrossRefPubMed
49.
go back to reference Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814–9.CrossRefPubMed Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814–9.CrossRefPubMed
50.
go back to reference Grąt M, Krasnodębski M, Patkowski W, et al. Relevance of pre-transplant α-fetoprotein dynamics in liver transplantation for hepatocellular cancer. Ann Transplant. 2016;21:115–24.CrossRefPubMed Grąt M, Krasnodębski M, Patkowski W, et al. Relevance of pre-transplant α-fetoprotein dynamics in liver transplantation for hepatocellular cancer. Ann Transplant. 2016;21:115–24.CrossRefPubMed
Metadata
Title
The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer
Authors
Michał Grąt, MD, PhD
Karolina M. Wronka, MD
Jan Stypułkowski
Emil Bik
Maciej Krasnodębski, MD
Łukasz Masior, MD
Zbigniew Lewandowski, PhD
Karolina Grąt, MD
Waldemar Patkowski, MD, PhD
Marek Krawczyk, MD, PhD
Publication date
01-02-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5500-0

Other articles of this Issue 2/2017

Annals of Surgical Oncology 2/2017 Go to the issue